NRx Pharmaceuticals, Inc.
NRXP
$2.35
$0.083.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 66.50% | -218.94% | 39.28% | -459.33% | 79.45% |
| Total Depreciation and Amortization | -- | -- | -- | -50.00% | 100.00% |
| Total Amortization of Deferred Charges | -- | -100.00% | -60.94% | 71.98% | -- |
| Total Other Non-Cash Items | -83.02% | 736.39% | -87.29% | 1,159.57% | -154.61% |
| Change in Net Operating Assets | 209.88% | -- | 100.00% | -300.00% | -98.59% |
| Cash from Operations | 28.23% | -15.75% | -65.87% | 9.02% | 9.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -149.78% | -90.96% | 20.83% | 40.70% | -- |
| Total Debt Repaid | 100.00% | 76.88% | 91.52% | -42.78% | -264,300.00% |
| Issuance of Common Stock | -- | -100.00% | -- | -100.00% | -93.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 269.37% | 389.14% | -122.85% | -0.39% | -- |
| Cash from Financing | 599.71% | -81.67% | 300.26% | -7.74% | -34.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 262.02% | -164.26% | 2,122.17% | 19.44% | -143.52% |